Abstract
Background: Elexacaftor/Tezacaftor/Ivacaftor (ETI) modulator therapy is often associated with increased body mass index (BMI) in people with cystic fi......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
